luteina

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

age-related cognitive decline

[Insufficient Evidence]

Dose: 10-12 mg PO qd

age-related macular degeneration

[Possibly Effective]

Dose: 5-20 mg PO qd

Alzheimer disease

[Insufficient Evidence]

Dose: 10 mg PO qd

asthenopia (eye strain)

[Insufficient Evidence]

Dose: 17.5 mg PO qd; Info: used with omega-3 fatty acids and bilberry

cataracts

[Possibly Effective]

Dose: 6-11.7 mg PO qd; Alt: 15 mg PO 3x/wk

child development

[Insufficient Evidence]

Dose: 10 mg PO qd; Info: for patients 5-12 yo

cognitive function

[Insufficient Evidence]

Dose: 10 mg PO qd; Info: given with high fat meal

dry eye disease

[Insufficient Evidence]

Dose: 6-20 mg PO qd

glaucoma

[Insufficient Evidence]

Dose: 10 mg PO qd

macular telangiectasia type 2

[Insufficient Evidence]

Dose: 10 mg PO qd

non-Hodgkin lymphoma

[Insufficient Evidence]

Dose: up to 20 mg PO qd

obesity

[Insufficient Evidence]

Dose: 10-20 mg PO qd

visual development, peds patients

[Insufficient Evidence]

Dose: 10 mg PO qd; Info: for patients 5-12 yo